| Autor: |
ALSTERHOLM, Mikael, SVEDBOM, Axel, ANDERSON, Chris D., SOMMAR, Lena HOLM, IVERT, Lina U., JOSEFSON, Anna, KOBYLETZKI, Laura von, LINDBERG, Magnus, LUNDEBERG, Lena, LUNDQVIST, Maria, NYLANDER, Elisabet, FALK, MariHelen SANDSTRÖM, SHAYESTEH, Alexander, SIGURDARDOTTIR, Gunnthorunn, SONESSON, Andreas, SVENSSON, Åke, VIRTANEN, Marie, VRANG, Sophie, WAHLGREN, Carl-Fredrik, BRADLEY, Maria |
| Předmět: |
|
| Zdroj: |
Acta Dermato-Venereologica; 2023, Vol. 103, p1-7, 7p |
| Abstrakt: |
SwedAD, a Swedish nationwide registry for patients with atopic dermatitis receiving systemic pharmacotherapy, was launched on 1 September 2019. We describe here the establishment of a user-friendly registry to the benefit of patients with atopic dermatitis. By 5 November 2022, 38 clinics had recorded 931 treatment episodes in 850 patients with an approximate national coverage rate of 40%. Characteristics at enrolment included median Eczema Area and Severity Index (EASI) 10.2 (interquartile range 4.0, 19.4), Patient-Oriented Eczema Measure (POEM) 18.0 (10.0, 24.0), Dermatology Life Quality Index (DLQI) 11.0 (5.0, 19.0) and Peak Itch Numerical Rating Scale-11 (NRS-11) 6.0 (3.0, 8.0). At 3 months, median EASI was 3.2 (1.0, 7.3) and POEM, DLQI, and NRS-11 were improved. Regional coverage varied, reflecting the distribution of dermatologists, the ratio of public to private healthcare, and difficulties in recruiting certain clinics. This study highlights the importance of a nationwide registry when managing systemic pharmacotherapy of atopic dermatitis. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
